Pipex Pharmaceuticals Announces Issuance of Additional US Patent Covering CD4 Inhibitor Molecules

ANN ARBOR, MI--(Marketwire - May 20, 2008) - Pipex Pharmaceuticals, Inc. (AMEX: PP), a specialty pharmaceutical company developing innovative late-stage drug candidates for the treatment of neurologic and autoimmune diseases, announced it was issued a United States patent that is part of its CD4 inhibitor patent estate. The issued patent, U.S. 7,345,020, entitled, "Mimetics of CD4 That Inhibit Immune Responses," covers new chemical entities relating to inhibitors of the highly studied CD4 T-cell receptor, a key protein in T-cell-Antigen Presenting Cell immunological synapse formation and T-cell activation critical in so-called CD4-mediated diseases such as transplantation, multiple sclerosis (MS), psoriasis, and rheumatoid arthritis (RA).
MORE ON THIS TOPIC